[{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Awarded NIH Grant","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Funding","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"SymBiosis and Khosla Ventures","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series C Financing","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures"}]